NDAORALCAPSULE
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
4/8 — Partial
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEPOSIA (ozanimod hydrochloride) is an oral sphingosine 1-phosphate (S1P) receptor modulator approved for treating ulcerative colitis and Crohn's disease. It works by sequestering lymphocytes in lymphoid tissues, reducing their migration to inflamed gut mucosa. The drug represents an alternative to injectable biologics and corticosteroids for moderate-to-severe inflammatory bowel disease.
$0.063BPart D
Peak11.9 years to LOEProduct is in peak commercial phase with 6,180 Part D claims in 2023; commercial team size and investment likely stable with focus on market penetration and patient retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
Started Jun 2026
15 enrolled
Multiple SclerosisProgressive Multifocal Leukoencephalopathy
Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study
Started Aug 2024
0Ulcerative Colitis
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
Started Mar 2021
450 enrolled
Multiple Sclerosis, Relapsing-Remitting
Career Relevance
ZEPOSIA careers center on mature brand management, payer strategy, and specialty gastroenterology engagement rather than launch-phase excitement. Roles emphasize competitive differentiation, patient persistence, and managed care negotiations in a crowded IBD market with stable but not explosive growth.
Worked on ZEPOSIA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.